2026-01-12 - Analysis Report
**Stock Report: Schrödinger Inc (SDGR)**
=====================================================

**Company Overview**
-------------------

Schrödinger Inc is a biotech company.

**Performance Comparison**
-------------------------

| Ticker | Cumulative Return | Divergence |
|--------|--------------------|------------|
| SDGR   | -53.37%           | -120.60    |
| VOO    | 67.27%            | N/A        |

**Divergence Analysis**
----------------------

* The current divergence is -120.60, indicating a significant difference in performance between SDGR and VOO.
* The relative divergence of 1.00% indicates that it is at the top 1% percentile of past data.

**Yearly Performance**
----------------------

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|-----|-------|-------|--------|
| 2021-2023 | -57.0% | 52.9% | -58.0% | 1.8 | 2.6B   |
| 2022-2024 | 6.0%  | 46.6% | -13.0% | 1.8 | 1.4B   |
| 2023-2025 | -4.0% | 46.6% | -66.0% | 1.8 | 1.3B   |

**Recent Stock Price Fluctuations**
----------------------------------

* Close: $18.39
* 5-day SMA: $18.61
* 20-day SMA: $18.20
* 60-day SMA: $18.67

**Indicators Analysis**
----------------------

* Market Risk Indicator (MRI): 0.70 (Medium Investment Recommended)
* RSI: 61.51
* PPO: 0.39
* Expected Return: -6400.50%

**News & Significant Events**
-----------------------------

[2025-12-22] BofA Upgrades Schrödinger (SDGR) to Buy After Strategic Pivot to Software
[2026-01-09] Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR?
[2026-01-07] UBS Initiates Coverage with Neutral Rating
[2026-01-09] Eli Lilly in pact with Schrödinger in AI-related drug discovery
[2026-01-07] Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%

**Analyst Opinions**
--------------------

**Analyst Consensus**:
* Key: Buy
* Mean (1=StrongBuy~5=Sell): 1.60 (~Buy)
* Opinions: 10
* Target Price (avg/high/low): 25.00 / 32.00 / 18.00

**Recent Earnings Analysis**
-----------------------------

| Date | EPS | Revenue |
|------|-----|----------|
| 2025-11-05 | -0.45 | 0.05 B  |
| 2025-08-06 | -0.59 | 0.05 B  |
| 2025-05-07 | -0.82 | 0.06 B  |
| 2024-11-12 | -0.52 | 0.04 B  |
| 2025-11-05 | -0.52 | 0.04 B  |

**Revenue and Profitability**
-----------------------------

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $0.05B | 51.61%       |
| 2025-06-30 | $0.05B | 47.77%       |
| 2025-03-31 | $0.06B | 52.26%       |
| 2024-12-31 | $0.09B | 72.61%       |
| 2024-09-30 | $0.04B | 50.24%       |

**Capital and Profitability**
------------------------------

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $0.32B | -10.21% |
| 2025-06-30 | $0.34B | -12.59% |
| 2025-03-31 | $0.37B | -16.01% |
| 2024-12-31 | $0.42B | -9.54% |
| 2024-09-30 | $0.45B | -8.49% |

**Comprehensive Analysis (Summary of previous items)**
---------------------------------------------------------

Based on the analysis, SDGR has underperformed the market, with a cumulative return of -53.37%. The recent stock price fluctuations indicate a sharp decline. The indicators analysis suggests a medium investment risk, with a high risk appetite. The news and significant events section highlights upgrades, initiations, and partnerships. The analyst opinions section shows a buy consensus with a target price of $25.00. The recent earnings analysis reveals a decline in revenue and EPS. The revenue and profitability section shows a fluctuating profit margin, while the capital and profitability section reveals a decline in equity and negative ROE.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.